d!NK Revenue and Competitors

Aberfoyle, AU

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • d!NK's estimated annual revenue is currently $1.3M per year.(i)
  • d!NK's estimated revenue per employee is $87,000

Employee Data

  • d!NK has 15 Employees.(i)

d!NK's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M3N/AN/AN/A
#2
$2.5M25N/AN/AN/A
#3
$0.5M14-22%$14.3MN/A
#4
$2.6M26N/AN/AN/A
#5
$0.5M11N/AN/AN/A
#6
$5.1M44N/AN/AN/A
#7
$0.2M3N/AN/AN/A
#8
$1M12N/AN/AN/A
#9
$1.1M11N/AN/AN/A
#10
$0.2M3N/AN/AN/A
#11
$0.9M10N/AN/AN/A
#12
$0.3M4N/AN/AN/A
Add Company

What Is d!NK?

keywords:N/A

N/A

Total Funding

15

Number of Employees

$1.3M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

d!NK News

2022-04-20 - Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

Presentations include an oral presentation by Wen Luo, Ph.D., ... NKTR-255 enhances anti-MCAM CAR NK cell cytotoxicity against Ewing sarcoma...

2022-04-17 - Latin AMAs 2022: The Best and Biggest Moments of the Night

NK said that, at this moment, her country is not just going through a ... D'Alessio and Nodal were each honored with two prestigious awards.

2022-04-13 - When killers become thieves: Trogocytosed PD-1 inhibits NK ...

5, A to D, y axis), showing that trogocytosis occurred in vivo. Strikingly, high levels of PD-1 were detected on the surface of NK cells only when tumor cells...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.7M11510%N/A